Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given an average recommendation of “Hold” by the twenty-one research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $111.53.

A number of research analysts have weighed in on ZBH shares. Truist Financial set a $101.00 price target on Zimmer Biomet in a research note on Tuesday, May 6th. Royal Bank of Canada decreased their price target on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a “buy” rating in a research note on Tuesday, May 6th. BTIG Research restated a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Finally, Wells Fargo & Company decreased their price target on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th.

Zimmer Biomet Stock Up 0.9%

Shares of Zimmer Biomet stock opened at $91.91 on Wednesday. The business’s 50 day simple moving average is $99.19 and its 200 day simple moving average is $104.50. Zimmer Biomet has a 52-week low of $89.22 and a 52-week high of $116.71. The firm has a market cap of $18.18 billion, a PE ratio of 20.65, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.94 EPS. On average, analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.24%.

Institutional Trading of Zimmer Biomet

Several institutional investors have recently added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Garde Capital Inc. bought a new stake in shares of Zimmer Biomet during the 1st quarter valued at $29,000. Menard Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Washington Trust Advisors Inc. bought a new stake in shares of Zimmer Biomet during the 1st quarter valued at $30,000. Finally, Columbia River Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter valued at $30,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.